APA

Cure H., Souteyrand P., Ouabdesselam R., Roche H., Ravaud A., D'incan M., Viens P., Fargeot P., Lentz M. A., Fumoleau P., Hanauske A. & Chollet P. (20000229). Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. : Melanoma research.

Chicago

Cure H, Souteyrand P, Ouabdesselam R, Roche H, Ravaud A, D'incan M, Viens P, Fargeot P, Lentz M A, Fumoleau P, Hanauske A and Chollet P. 20000229. Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. : Melanoma research.

Harvard

Cure H., Souteyrand P., Ouabdesselam R., Roche H., Ravaud A., D'incan M., Viens P., Fargeot P., Lentz M. A., Fumoleau P., Hanauske A. and Chollet P. (20000229). Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. : Melanoma research.

MLA

Cure H, Souteyrand P, Ouabdesselam R, Roche H, Ravaud A, D'incan M, Viens P, Fargeot P, Lentz M A, Fumoleau P, Hanauske A and Chollet P. Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. : Melanoma research. 20000229.